Details of the Drug
General Information of Drug (ID: DMX3KRQ)
Drug Name |
N-hydroxy-2,2-diphenylacetamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, >
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 227.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||